Mark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.
Updates to NCCN Guidelines for CNS Cancers Pinpoint the Importance of Testing
May 21st 2023In an interview with Targeted Oncology, Craig Horbinski, MD, PhD, discussed recent recommendations and NCCN guidelines regarding the molecular profiling of gliomas and other central nervous system cancers.
Read More
New Technologies, Holistic Treatment Approaches for Brain Cancer Emerging
May 17th 2023For Brain Cancer Awareness Month, Charles Redfern, MD, discussed the biggest technological changes to treatment for adult patients with brain cancer and how holistic treatment remains important for treating this challenging disease.
Read More
Nivolumab Combinations Improve Survival But Are Not Cost-Prohibitive in Advanced ESCC
May 9th 2023An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.
Read More
2 Clarke Drive
Cranbury, NJ 08512